Mavacamten Controlled Hypertrophic Cardiomyopathy for >1 Year - Medscape

Open-label mavacamten for a median of 62 weeks in patients with symptomatic obstructive hypertrophic cardiomyopathy showed ongoing safety and efficacy.

WASHINGTON  Treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy who remained on treatment with the investigational agent mavacamten for a median of 62 weeks continued to sh… [+4302 chars]

full article...